case_images: PMC9582938_01
case_images: Case presentation during treatment. (A) H&E staining of ovarian clear cell carcinoma. (B) Scheme of molecular testing strategy. (C) Change of serum CA125 levels during the treatment.
case_images: fimmu-13-951422-g001.jpg
case_images: PMC9582938_01_fimmu-13-951422-g001.jpg
case_images: f1
case_images: The postoperative pathology was diagnosed with OCCC at stage IC2 (T1c2N0M0) (  Figure 1A  ). During this period, the CA125 levels were below normal (  Figure 1C  ). To investigate more effective treatment, tumor tissue and blood samples were tested for the feasibility of target therapies (  Figure 1B  ). The tumor mutation burden (TMB) was 1.24 mut/Mb ( Figure 1B ).
case_images: Timeline of the case and MRI findings. (A) Timeline of patient diagnosis, prior therapies, and immunotherapy. (B) MRI scans demonstrating activity (i.e., complete response) to Camrelizumab. The lymph node metastases were located in front of the inferior vena cava (red arrows) in column 1, anterior to the tail of the pancreas (red arrows) in column 3, and around the head of the pancreas (red arrows) in column 3.
case_images: fimmu-13-951422-g002.jpg
case_images: PMC9582938_01_fimmu-13-951422-g002.jpg
case_images: f2
case_images: Meantime, MRI revealed lymph node metastases located in front of the inferior vena cava (the biggest mass was 4.5*2.0 cm) and other enlarged peripancreatic nodes, which suggested progressive disease (PD) ( Figure 2B ). The patient was administered Camrelizumab (200 mg) every 2 weeks ( Figure 2A ). The results showed reduced lymph node metastases (short axis < 10 mm) and normal tumor markers, which were suggested as iCR by iRECIST criteria ( Figure 2A ). The timeline of patient treatment and change of tumor markers is shown in  Figure 2A .